HETERO LABS LIMITED
Location
Telangana
Founded
1989-03-10
Website
Risk Signals
263 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about HETERO LABS LIMITED
Live alerts from global media, monitored by Business Radar
2025-01-05 (rbc.ru)
How the deal with Gilead illustrates India's transformation into a “forge of generics” - RBC Industries
India is one of the leaders in the market of generics, inexpensive alternatives to patented drugs. At the end of 2024, the country strengthened its position by concluding a deal with Gilead Sciences Ireland and planning the joint production of an “HIV vaccine”
Read more
2024-10-04 (biospectrumindia.com)
Dr. Reddy’s, Hetero sign voluntary licensing agreement with Gilead Sciences to transform global HIV response
Dr. Reddy’s, Hetero sign voluntary licensing agreement with Gilead Sciences to transform global HIV response
Read more
2024-10-03 (prnewswire.co.uk)
Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
/PRNewswire/ -- Hetero, India's leading pharmaceutical company with the widest global reach, today announced a new partnership with Gilead Sciences Ireland UC...
Read more
2020-11-28 (newindianexpress.com)
Hyderabad-based Hetero Drugs to produce 100 million Sputnik V vaccine doses per year
HYDERABAD: Hyderabad-based pharmaceutical company Hetero Drugs has reached an agreement with the Russian Direct Investment Fund (RDIF) to produce over 100 milli
Read more
2011-01-29 (newindianexpress.com)
Hetero, Matrix sign deal with Irish firm
HYDERABAD: Two city-based pharmaceutical companies — Hetero Drugs and Matrix Labs — have obtained the licensing, manufacturing and commercialisation rights to manufacture and market Rilpivirin
Read more
(fiercepharma.com)
Asia—GSK's India Zantac plant sale; Takeda-BridGene drug discovery pact; Celltrion's COVID antibody
GlaxoSmithKline is selling its Zantac plant in India for a fraction of its original investment in the wake of a global recall. | GlaxoSmithKline sold a Zantac plant in India to Hetero Labs in the wake of a global recall. Takeda penned a drug discovery pact with BridGene focused on neurodegenerative disease. Celltrion's COVID-19 antibody won backing from EMA's drug reviewers ahead of an official nod. And more.
Read more